Australian biotech market watch 05/06/09
Friday, 05 June, 2009
It's been a strong week of trading, with the All Ordinaries buoyed by positive news on the Australian economy, a strong performance in overseas exchanges, a rising then flattening Aussie dollar and news of Rio Tinto and BHPs machinations towards a merger in Western Australia.
Overall, as of around 4pm, the All Ordinaries is up nearly 1%, which is a lift of 2% over the week, although profit taking has clipped some of the gains.
By contrast, the health indices dropped 2.5% today, shedding virtually all the gains of the past week.
Leading the drop is CSL (ASX:CSL), which shed $1.00 to $29.01. This comes after the appointment of the judge to hear the US antitrust case against CSL that might block CSL's US$3.1 billion takeover of plasma group, Talecris Biotherapeutics.
Ramsey Health Care (ASX:RHC) also shed 15c to $10.95, and ResMed (ASX:RMD) gave up 10c to $4.68 as it continues with its buy-back of up to 10 million common shares.
Sonic Healthcare (ASX:SHL), which some analysts consider a good defensive stock in this market, also dropped 50c to $11.30.
It wasn't all bad news though. Cochlear (ASX:COH) rose 0.4% to $57.94, and dental outfit, 1300 Smiles (ASX:ONT) rose 5.4% to $2.74.
Other stocks remained fairly static.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
